{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:56:47Z","timestamp":1792439807936,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,25]]},"DOI":"10.7759\/cureus.17439","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T15:41:19Z","timestamp":1629906079000},"source":"Crossref","is-referenced-by-count":13,"title":["Use of Intravitreal Methotrexate Infusion in Complicated Retinal Detachment for Prevention of Proliferative Vitreoretinopathy in a Pilot Study"],"prefix":"10.7759","author":[{"given":"Sana","family":"Jahangir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tehmina","family":"Jahangir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad H","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qasim","family":"Lateef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uzma","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon","family":"Tayyab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0000000000000258","article-title":"Proliferative vitreoretinopathy: a review","volume":"59","author":"Idrees S","year":"2019","unstructured":"Idrees S, Sridhar J, Kuriyan AE. Proliferative vitreoretinopathy: a review. Int Ophthalmol Clin. 2019, 59:221-240. 10.1097\/IIO.0000000000000258","journal-title":"Int Ophthalmol Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s1350-9462(97)00007-4","article-title":"Risk factors for proliferative vitreoretinopathy","volume":"17","author":"Nagasaki H","year":"1998","unstructured":"Nagasaki H, Shinagawa K, Mochizuki M. Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res. 1998, 17:77-98. 10.1016\/s1350-9462(97)00007-4","journal-title":"Prog Retin Eye Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S111893","article-title":"Intravitreal methotrexate infusion for proliferative vitreoretinopathy","volume":"10","author":"Sadaka A","year":"2016","unstructured":"Sadaka A, Sisk RA, Osher JM, Toygar O, Duncan MK, Riemann CD. Intravitreal methotrexate infusion for proliferative vitreoretinopathy. Clin Ophthalmol. 2016, 10:1811-1817. 10.2147\/OPTH.S111893","journal-title":"Clin Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000360466","article-title":"Proliferative vitreoretinopathy","volume":"54","author":"Claes C","year":"2014","unstructured":"Claes C, Lafet\u00e1 AP. Proliferative vitreoretinopathy. Dev Ophthalmol. 2014, 54:188-195. 10.1159\/000360466","journal-title":"Dev Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2015.114","article-title":"Intra-silicone oil injection of methotrexate at the end of vitrectomy for advanced proliferative diabetic retinopathy","volume":"29","author":"Ghasemi Falavarjani K","year":"2015","unstructured":"Ghasemi Falavarjani K, Modarres M, Hadavandkhani A, Karimi Moghaddam A. Intra-silicone oil injection of methotrexate at the end of vitrectomy for advanced proliferative diabetic retinopathy. Eye (Lond). 2015, 29:1199-1203. 10.1038\/eye.2015.114","journal-title":"Eye (Lond)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2013.12.006","article-title":"Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?","volume":"40","author":"Pennock S","year":"2014","unstructured":"Pennock S, Haddock LJ, Eliott D, Mukai S, Kazlauskas A. Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?. Prog Retin Eye Res. 2014, 40:16-34. 10.1016\/j.preteyeres.2013.12.006","journal-title":"Prog Retin Eye Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/BF02181181","article-title":"The development of severe proliferative vitreoretinopathy after retinal detachment surgery. Grade B: a determining risk factor","volume":"226","author":"Bonnet M","year":"1988","unstructured":"Bonnet M. The development of severe proliferative vitreoretinopathy after retinal detachment surgery. Grade B: a determining risk factor. Graefes Arch Clin Exp Ophthalmol. 1988, 226:201-205. 10.1007\/BF02181181","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/BF00292353","article-title":"Preoperative vitreous hemorrhage associated with rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy?","volume":"234","author":"Duquesne N","year":"1996","unstructured":"Duquesne N, Bonnet M, Adeleine P. Preoperative vitreous hemorrhage associated with rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy?. Graefes Arch Clin Exp Ophthalmol. 1996, 234:677-682. 10.1007\/BF00292353","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/BF00176431","article-title":"A multivariate analysis of anatomic success of retinal detachments treated with scleral buckling","volume":"232","author":"Grizzard WS","year":"1994","unstructured":"Grizzard WS, Hilton GF, Hammer ME, Taren D. A multivariate analysis of anatomic success of retinal detachments treated with scleral buckling. Graefes Arch Clin Exp Ophthalmol. 1994, 232:1-7. 10.1007\/BF00176431","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31030","article-title":"Fibrosis and diseases of the eye","volume":"117","author":"Friedlander M","year":"2007","unstructured":"Friedlander M. Fibrosis and diseases of the eye. J Clin Invest. 2007, 117:576-586. 10.1172\/JCI31030","journal-title":"J Clin Invest"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2217\/bmm.13.65","article-title":"Defining the seriousness of proliferative vitreoretinopathy by aspiration of cytokines from the anterior chamber","volume":"7","author":"Rusnak S","year":"2013","unstructured":"Rusnak S, Vrzalova J, Hecov\u00e1 L, Kozova M, Topolcan O, Ricarova R. Defining the seriousness of proliferative vitreoretinopathy by aspiration of cytokines from the anterior chamber. Biomark Med. 2013, 7:759-767. 10.2217\/bmm.13.65","journal-title":"Biomark Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.01.021","article-title":"Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial","volume":"124","author":"Banerjee PJ","year":"2017","unstructured":"Banerjee PJ, Quartilho A, Bunce C, Xing W, Zvobgo TM, Harris N, Charteris DG. Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial. Ophthalmology. 2017, 124:757-767. 10.1016\/j.ophtha.2017.01.021","journal-title":"Ophthalmology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006421.pub3","article-title":"Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery","volume":"1","author":"Sundaram V","year":"2013","unstructured":"Sundaram V, Barsam A, Virgili G. Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Cochrane Database Syst Rev. 2013, 1:CD006421. 10.1002\/14651858.CD006421.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.08.042","article-title":"Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy","volume":"114","author":"Wickham L","year":"2007","unstructured":"Wickham L, Bunce C, Wong D, McGurn D, Charteris DG. Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology. 2007, 114:698-704. 10.1016\/j.ophtha.2006.08.042","journal-title":"Ophthalmology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2014.21","article-title":"Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy","volume":"28","author":"Ghasemi Falavarjani K","year":"2014","unstructured":"Ghasemi Falavarjani K, Hashemi M, Modarres M, Hadavand Khani A. Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy. Eye (Lond). 2014, 28:576-580. 10.1038\/eye.2014.21","journal-title":"Eye (Lond)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4103\/2008-322X.188390","article-title":"Intravitreal injection of bevacizumab in primary vitrectomy to decrease the rate of retinal redetachment: a randomized pilot study","volume":"11","author":"Tousi A","year":"2016","unstructured":"Tousi A, Hasanpour H, Soheilian M. Intravitreal injection of bevacizumab in primary vitrectomy to decrease the rate of retinal redetachment: a randomized pilot study. J Ophthalmic Vis Res. 2016, 11:271-276. 10.4103\/2008-322X.188390","journal-title":"J Ophthalmic Vis Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-20912","article-title":"Effect of methotrexate on an in vitro patient-derived model of proliferative vitreoretinopathy","volume":"58","author":"Amarnani D","year":"2017","unstructured":"Amarnani D, Machuca-Parra AI, Wong LL, et al.. Effect of methotrexate on an in vitro patient-derived model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2017, 58:3940-3949. 10.1167\/iovs.16-20912","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.06.002","article-title":"Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma","volume":"142","author":"Hardwig PW","year":"2006","unstructured":"Hardwig PW, Pulido JS, Erie JC, Baratz KH, Buettner H. Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol. 2006, 142:883-885. 10.1016\/j.ajo.2006.06.002","journal-title":"Am J Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002774","article-title":"Corneal toxicity of intravitreal methotrexate used for the treatment of proliferative vitreoretinopathy in silicone oil-filled eyes: a case series","author":"Shen-Sampas JH","year":"2021","unstructured":"Shen-Sampas JH, Ahmad TR, Stewart JM. Corneal toxicity of intravitreal methotrexate used for the treatment of proliferative vitreoretinopathy in silicone oil-filled eyes: a case series. Cornea. 2021, 10.1097\/ICO.0000000000002774","journal-title":"Cornea"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1597894","article-title":"Intra-silicone oil injection of methotrexate in retinal reattachment surgery for proliferative vitreoretinopathy","volume":"28","author":"Falavarjani KG","year":"2020","unstructured":"Falavarjani KG, Hadavandkhani A, Parvaresh MM, Modarres M, Naseripour M, Alemzadeh SA. Intra-silicone oil injection of methotrexate in retinal reattachment surgery for proliferative vitreoretinopathy. Ocul Immunol Inflamm. 2020, 28:513-516. 10.1080\/09273948.2019.1597894","journal-title":"Ocul Immunol Inflamm"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2019-000293","article-title":"Intravitreal methotrexate for the treatment of proliferative vitreoretinopathy","volume":"4","author":"Benner JD","year":"2019","unstructured":"Benner JD, Dao D, Butler JW, Hamill KI. Intravitreal methotrexate for the treatment of proliferative vitreoretinopathy. BMJ Open Ophthalmol. 2019, 4:e000293. 10.1136\/bmjophth-2019-000293","journal-title":"BMJ Open Ophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1159\/000500271. 4.","article-title":"Repeated injection of methotrexate into silicone oil-filled eyes for grade c proliferative vitreoretinopathy: a pilot study","volume":"242","author":"Nourinia R","year":"2019","unstructured":"Nourinia R, Borna F, Rahimi A, et al.. Repeated injection of methotrexate into silicone oil-filled eyes for grade c proliferative vitreoretinopathy: a pilot study. Ophthalmologica. 2019, 242:113-117. 10.1159\/000500271. 4.","journal-title":"Ophthalmologica"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/65902-use-of-intravitreal-methotrexate-infusion-in-complicated-retinal-detachment-for-prevention-of-proliferative-vitreoretinopathy-in-a-pilot-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:56Z","timestamp":1707506996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/65902-use-of-intravitreal-methotrexate-infusion-in-complicated-retinal-detachment-for-prevention-of-proliferative-vitreoretinopathy-in-a-pilot-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.17439","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,25]]}}}